Regulatory 2024-09-05 | Ascelia Pharma Announces Final Outcome in Fully Subscribed SEK 105 Million Rights Issue PDF Report Presentation Webcast
Regulatory 2024-09-04 | Ascelia Pharma Announces Preliminary Outcome in Rights Issue PDF Report Presentation Webcast
Regulatory 2024-08-16 | Ascelia Pharma Announces Prospectus in Connection with Rights Issue PDF Report Presentation Webcast
Regulatory 2024-08-15 | Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 Study PDF Report Presentation Webcast
Regulatory 2024-08-14 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 14 August 2024 PDF Report Presentation Webcast
Regulatory 2024-08-09 | Ascelia Pharma Announces Final Terms of Rights Issue PDF Report Presentation Webcast
Regulatory 2024-07-10 | Notice of Extraordinary General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2024-07-10 | Ascelia Pharma Carries Out a Rights Issue of Units of Approximately SEK 105 Million to Fully Finance the NDA Submission for Orviglance® PDF Report Presentation Webcast
Regulatory 2024-05-16 | Quarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 Study PDF Report Presentation Webcast
2024-05-07 | Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Patients PDF Report Presentation Webcast
Regulatory 2024-05-06 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2024 PDF Report Presentation Webcast
Regulatory 2024-05-02 | Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study PDF Report Presentation Webcast
2024-04-18 | Ascelia Pharma Draws Down SEK 15 Million Second Tranche Under Existing Loan Facility PDF Report Presentation Webcast
2024-04-10 | Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024 PDF Report Presentation Webcast
Regulatory 2024-04-08 | Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024 PDF Report Presentation Webcast
Regulatory 2024-03-27 | Notice of Annual General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2024-02-09 | Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May PDF Report Presentation Webcast
Regulatory 2024-02-04 | Ascelia Pharma Secures Financing of up to SEK 35 Million PDF Report Presentation Webcast
